Ancora Heart Collaborated with egnite to Facilitate Clinical Trial Enrollment in (CORCINCH-HF) Trial for Heart Failure Patients
- The companies collaborated to accelerate clinical trial enrollment for the (CORCINCH-HF) trial evaluating the safety and efficacy of the AccuCinch Ventricular Restoration system in heart failure patients
- Both companies will combine their cutting-edge technology and expertise to deliver innovative therapies to HF patients faster
- The use of egnite’s trial accelerator AI technology efficiently identifies eligible patient candidates for pivotal clinical trials & the program launched at The Christ Health Network. Other participating (CORCINCH-HF) sites will also make use of egnite's Trial accelerator technology to promote patient identification & enrolment for the pivotal trial
Ref: BusinessWire | Image: Ancora Heart
Related News:- Ancora Heart Reports 12 Month Results of AccuCinch System for the Treatment of Patients with Heart Failure
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].